Company
Raphael Pharmaceutical Inc. · OTCQB: RAPH
A public-company context built around source-linked science, corporate updates, governance and public-record gateways.
About Raphael
Investor Relations · OTCQB: RAPH
Science. Commercialization. The next stage of Raphael.
Find public company updates, governance resources, filings and presentations.
Investment overview
A public IR center designed around source records.
Raphael Pharmaceutical Inc. (OTCQB: RAPH) connects an evidence-led scientific platform, a rheumatoid-arthritis lead research program, a distinct wellness initiative and public-company transparency. Public information remains available without login.
Science & pipeline
Rheumatoid arthritis lead research
Completed proof-of-concept research is a documented milestone. The evidence record explains study context and reported outcomes without presenting an approved-treatment claim.
Review RA evidenceDevelopment strategy
A disciplined next stage
Research and commercial decisions remain distinct. No unverified trial phase, timing, financing or development commitment is presented here.
Explore Science & PipelineCommercial initiative
RaphaWell
A distinct wellness initiative within the broader Raphael ecosystem. It is not presented as an approved pharmaceutical treatment.
Explore RaphaWellPublic transparency
SEC filings & governance
Public-record gateways, governance context and current-source boundaries are available without portal access.
Open SEC filingsInvestor pathway
News & evidence
Explore company updates, publications and the latest research from Raphael.
Explore News & PublicationsMilestones
Research milestones and the next stage of development.
Each milestone is linked to its appropriate source or corporate pathway so investors can distinguish reported research from future strategy.
Research
Proof-of-concept completed
Completed rheumatoid-arthritis proof-of-concept research is a reported milestone. Study design, DAS28 context and source-reported results remain connected to the evidence record.
Review RA evidenceDevelopment
Next-stage strategy
Raphael is organizing the next stage of its scientific development. Specific clinical phases, trial commitments and timelines are not asserted without an approved disclosure.
Explore the scientific platformCommercial initiative
RaphaWell pathway
RaphaWell is a distinct wellness/commercial pathway. The public application owns its consumer information, program terms and purchase experience.
Explore RaphaWellCorporate transparency
Source-led public record
Public filings, governance, company updates and presentations are maintained as separate, clearly labeled investor resources.
Open public recordsStock information
Raphael Pharmaceutical · RAPH
Use the official OTC Markets record for current market information. The compact stock bar at the top of this website displays a verified quote when available; otherwise it shows “Quote unavailable.” Quote timestamps and any stated delay should be read before relying on market data.
SEC filings
A useful direct gateway to the issuer record.
Raphael does not recreate SEC filing metadata, figures or market data on this page. The authoritative issuer record remains the source for availability and reporting status.
Authoritative source
SEC EDGAR issuer record
Use the SEC issuer lookup for Raphael Pharmaceutical Inc. (CIK 1415397). Review each filing directly in EDGAR before relying on it.
Public-company information
Investor Relations overview
Return to the public investor center for company context, milestones, governance, IP and source-linked updates.
News & evidence
Dated source records
Company updates, study materials and publication records remain categorized and linked to their sources.
Presentations
Current materials, clearly dated.
The September 17, 2026 management presentation replay is available below. An approved current downloadable investor slide deck has not been supplied; contact Investor Relations for current materials.
Video replay · September 17, 2026
Raphael Pharmaceutical — Life Sciences Virtual Investor Forum
Watch the published management presentation and Q&A from September 17, 2026. Statements reflect that date; consult current filings and scientific records for later developments.
Watch the investor presentation on YouTube ↗ · Organizer event record ↗
Patents & intellectual property
Patent and intellectual property records.
The legacy source map identifies a reported provisional application related to neutrophil-dominant autoimmune diseases, including rheumatoid arthritis. A provisional application is not presented as an issued patent; current legal status requires counsel confirmation.
Reported provisional record
U.S. Provisional Patent Application No. 63/911,729
A company-hosted release identifies this reported provisional application and its related research context. Review the source record directly; legal status, scope and rights require confirmation.
Company-reported indications
Company-provided descriptions of provisional application No. 63/911,729 (internal reference TRMB-RAPH-P-038-USP) include, among other indications:
- Rheumatoid Arthritis (RA)
- Psoriatic Arthritis
- Inflammatory Bowel Diseases (IBD)
- Systemic Lupus Erythematosus (SLE) involving neutrophilic activity
- Gout
These are company-reported indications included in the application description, not independent patent-office or clinical validation. A provisional application is not an issued patent and does not establish a treatment or efficacy claim for RaphaWell. Legal status, scope, ownership and any subsequent filing require counsel confirmation.
Controlled public gateway
Patents & IP library
Explore the intellectual-property record, related research and legal-status qualifications.
Governance
Public documents in the right context.
Private Board materials are available only to separately authorized accounts.
Public governance
Code of Ethics & approved documents
Company-approved governance documents will appear here as they become available.
Review company governanceInvestor contact
A clear public route for questions.
Use the contact page for Investor Relations enquiries.
Investor Relations
Use the corporate contact center to route an Investor Relations inquiry.